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Mark A Wainberg1* and Andrew Lever2It is fair to say that the HIV/AIDS epidemic is unprece-
dented for a number of different reasons. As another
World AIDS Day approaches on December 1, it behooves
us to take stock of the progress that has been made and
reflect on the road that still lies ahead.
First, who can remember another disease that arose as
quickly as HIV did in the early 1980s to infect millions of
people around the world, almost all of whom succumbed
to their illnesses at a time that antiretroviral (ARV) drugs
were non-available. Second, the development of safe
and well-tolerated ARVs over the past 25 years has now
resulted in a situation in which almost all infected persons,
who are fortunate to live in wealthy countries, can
aspire to live for many years, as HIV disease has been
transformed into a chronic manageable condition. Of
course, many problems remain, not the least of which
is that HIV continues to spread to millions more people
each year. In addition, people who live in developing
countries are often treated with inferior drugs compared
to those that are now available in wealthier settings and
are, therefore, less likely to fully benefit from the treatment
advances that have taken place.
Against this background, there is now a widespread
consensus that the only truly effective way to deal with
the HIV epidemic over the long term will be to find a
cure. First, although the global programmes that exist to
provide ARVs to people in developing countries (who
could not otherwise afford them) have been successful,
they may well be unsustainable over the long term for
reasons of cost. Simply put, the total costs may well
exceed hundreds of billions of dollars over the next
decade and many health care economists have sounded
the alarm that the West may not be able to provide this
necessary assistance unless the worldwide economy
improves. Second, it is no panacea for anyone to need
to take drugs every day for the rest of their life. And,* Correspondence: mark.wainberg@mcgill.ca
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article, unless otherwise stated.so far at least, the quest for an effective HIV vaccine
has fallen flat, in spite of valiant and insightful efforts
by scientists throughout the world.
In contrast, the optimism that now exists in regard
to potential curative strategies is palpable [1,2]. Among
other considerations, we now possess a much fuller
understanding of the problems involved and recognize
that HIV has been able to establish itself in latent
form in long-lived cellular reservoirs that cannot be
easily targeted by currently available ARVs [3]. This
has resulted in a large number of novel concepts that
are aimed at the reactivation of these reservoirs, so
that latently infected cells may be effectively targeted
by more traditional drugs [4]. In almost all western
countries, both public and private granting agencies
have now established dedicated funding programmes
that seek to attain a cure for HIV. And, for the first
time, a large critical mass of scientists are fully engaged
in this effort. Indeed, the goal of finding a cure for HIV
was highlighted at the recent Frontiers in Retrovirology
conference in Cambridge, United Kingdom, where more
than 300 scientists converged to discuss this topic. These
individuals are working on a large variety of approaches
that share this same goal. Hopefully, at least some of these
efforts will be successful.
It is also important to point out that research is flour-
ishing in a number of related areas as well. For example,
the success of current ARV usage in the treatment of
HIV has provided benefits to both society as a whole as
well as to individuals. We now know that people who
are successfully treated have vastly diminished viral loads
in their bodies and, as a consequence, are far less able to
transmit HIV than would otherwise happen [5,6]. On a
population level, it has been shown that the use of ARVs
has led to significant reductions in community viral load,
which refers to the average viral burden in a community
of HIV- infected individuals.
These observations have given rise to efforts to both
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be at risk for acquisition of HIV in programmes that are
referred to as pre-exposure prophylaxis (PrEP) [7]. To
date, certain of these studies suggest that PrEP may be
able to protect as many as 50% of individuals at risk
from acquisition of HIV, so long as they take their ARVs
as prescribed.
There has also been stimulation of a related area of
research termed Treatment as Prevention (TasP) that
holds that the successful mass use of ARVs will lead to
diminished viral loads across populations, such that
the transmission of new HIV infections will be greatly
reduced or halted [8]. Although concerns have often been
expressed that the development of HIV drug resistance
and the transmission of drug-resistant viruses might
thwart such efforts, the recent development of novel
compounds that may not be as prone to drug resistance
as earlier drugs may help to provide a solution to this
problem.
We have more of a right to be optimistic today than
at any time since the outbreak of the HIV epidemic.
Hopefully, we are now closer to the end than to the
beginning of the HIV epidemic and the observation of
World AIDS Day will ultimately become a cause for
celebration of our cumulative success.Authors’ information
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